Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this expanded access program is to provide ocrelizumab as treatment
for eligible participants with primary progressive multiple sclerosis (PPMS) before it is
commercially available in the United States (U.S.) for the indication of PPMS.